FindTrial
Sign In

A study to observe the side effects and patient recovery following administration of a Clot breaking drug called Alteplase in a stroke patient in a tertiary care hospital.

Safety and clinical effectiveness of Alteplase in acute ischemic stroke: An observational study in a tertiary care hospital.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/04/013094
Enrollment
25
Registered
2018-04-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- good

Interventions

None listed

Sponsors

Department of Pharmacolog
Lead Sponsor
Bangur institute of neuroscience
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: patients aged 18 to 80 years diagnosed with acute ischemic stroke and who has been administered Alteplase would be included.

Exclusion criteria

Exclusion criteria: Those who are contraindicated for thrombolysis.

Design outcomes

Primary

MeasureTime frame
1. Assessment of safety profile of Alteplase administration in acute ischemic stroke 2.Assessment of major neurological improvement using National Institute of Health Stroke Scale ( NIHSS) at 2 hour and 24- 36 hour.Timepoint: NIHSS scoring at 2 hour and 24- 36 hour.—

Secondary

MeasureTime frame
assessment of short term functional outcome using Modified Ranking ScaleTimepoint: day 7 or earlier( if discharged earlier) Day 90.—

Countries

India

Contacts

Public ContactDonik peter

IPGMER and SSKM hospital

drsupchat@gmail.com8910483298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026